Sex-Med - sex-specific evidence on heart failure medication safety and effectiveness to support sex-specific treatment recommendations and improve treatment in women

Dutch women treated with cardiovascular (CV) medications (n=767,000) have twice the risk of adverse drug events (ADEs) compared with men, which reduces treatment benefit. This is especially pressing for women with heart failure (HF) (n=19,760, 52% of all patients) because HF predisposes them to ADEs beyond biological differences in drug metabolism and increased risk of drug-drug interactions due to polypharmacy. This project has two aims. First, generating evidence on sex differences for in the effectiveness and safety of HF medications that meets the quality standards required for incorporation in formal treatment guidelines. Second, translating this evidence to practice.

Covid Vaccine Monitor - develop and explore methods for vaccine safety research

Provide methodological support in a project on adverse events of Covid-19 vaccines. This includes providing study design and analysis suggestions, testing assumptions underlying methods used, and performing sensitivity analyses.